Everything drug pricing and policy, every day
Plus assessing whether CMS’ Bridge program will be ginormous or merely huge
And trying to make sense of an ADA poll showing that most patients with diabetes pay more than $35 a month for insulin
And drug launch prices fell like a rock last year (but you can’t really read anything into that)
And pharma companies take aim at the reluctance of European countries to boost medicine spending
And a 340B hospital in Virginia finds a novel way of not helping vulnerable patients
Plus a couple of 340B links and a study on the impact of the Medicare Part D out-of-pocket cap
And a new report adds up the impact on drug development from the chaos across the innovation ecosystem
And the Trump administration moves ahead with MFN rules as European governments weigh the impacts
